- Home
- APLM vs CANF Comparison
APLM vs CANF Comparison
Compare APLM & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- CANF
- Stock Information
- Founded
- APLM 2016
- CANF 1994
- Country
- APLM United States
- CANF Israel
- Employees
- APLM N/A
- CANF N/A
- Industry
- APLM Blank Checks
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- APLM Finance
- CANF Health Care
- Exchange
- APLM Nasdaq
- CANF Nasdaq
- Market Cap
- APLM 15.6M
- CANF 14.4M
- IPO Year
- APLM N/A
- CANF N/A
- Fundamental
- Price
- APLM $10.13
- CANF $1.54
- Analyst Decision
- APLM Strong Buy
- CANF Strong Buy
- Analyst Count
- APLM 2
- CANF 2
- Target Price
- APLM $425.00
- CANF $14.00
- AVG Volume (30 Days)
- APLM 71.6K
- CANF 1.2M
- Earning Date
- APLM 02-15-2025
- CANF 02-03-2025
- Dividend Yield
- APLM N/A
- CANF N/A
- EPS Growth
- APLM N/A
- CANF N/A
- EPS
- APLM N/A
- CANF N/A
- Revenue
- APLM $2,101,000.00
- CANF $667,000.00
- Revenue This Year
- APLM N/A
- CANF $409.56
- Revenue Next Year
- APLM N/A
- CANF N/A
- P/E Ratio
- APLM N/A
- CANF N/A
- Revenue Growth
- APLM 70.54
- CANF N/A
- 52 Week Low
- APLM $6.50
- CANF $1.29
- 52 Week High
- APLM $105.00
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- APLM 51.32
- CANF 41.92
- Support Level
- APLM $9.16
- CANF $1.41
- Resistance Level
- APLM $11.74
- CANF $1.54
- Average True Range (ATR)
- APLM 1.40
- CANF 0.10
- MACD
- APLM 0.37
- CANF 0.02
- Stochastic Oscillator
- APLM 69.27
- CANF 57.14
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).